HomeFile

File

View Category
Antiplatelet

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients, JACC publishes...
solaci -
Learn More
Chronic Ischemic cardiopathy

Silent Diabetes Is the New Stealthy Enemy

One in three “nondiabetic” patients who undergo angioplasty with current drug-eluting stents have an altered glucose metabolism,...
solaci -
Learn More
Structural heart disease

Next-Day Discharge after TAVR: Is It Viable?

Next-day discharge after transfemoral transcatheter aortic valve replacement (TAVR) might be viable, with no major complications at 30 days...
solaci -
Learn More
Acute coronary syndromes

Complete Revascularization Is Beneficial in Acute MI with Cardiogenic Shock

Around half of all cases of ST-segment elevation acute myocardial infarction (STEMI) come alongside lesions in another...
solaci -
Learn More
Coronary disease

Keys to Productivity Improvement in the Cath Lab

The systematic reduction of inefficiencies in the catheterization laboratory (such as the improvement of lab room start...
solaci -
Learn More
Peripheral vascular disease

What Is the Prognosis for Reinterventions in Critical Lower Limb Ischemia?

Infrapopliteal (below the knee, BTK) percutaneous transluminal angioplasty (PTA) has been acknowledged as a useful strategy in...
solaci -
Learn More
Structural heart disease

Red Light for TAVR in Low Surgical Risk Patients

A new study raises an alarm against expanding transcatheter aortic valve replacement (TAVR) procedures to low surgical risk...
solaci -
Learn More
Institutional News

Win a Grant to the C3 in Orlando, Florida

From June 27th to June 30th, Orlando, Florida will hold the Complex Cardiovascular Catheter Therapeutics (C3 Conference),...
solaci -
Learn More